High acceptability and viral suppression of patients on Dolutegravir-based first-line regimens in pilot sites in Uganda: A mixed-methods prospective cohort study

Uganda adopted the integrase inhibitor dolutegravir (DTG) as part its preferred first-line HIV treatment regimen in 2018. Prior to the national rollout, the Uganda Ministry of Health and Clinton Health Access Initiative (CHAI) launched a pilot study in July 2017 aimed at better understanding patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Nabitaka, Vennie Mbaziira, Nawaggi, Pamela, Campbell, Jennifer, Conroy, James, Harwell, Joseph, Magambo, Kinanga, Middlecote, Caroline, Caldwell, Benvy, Katureebe, Cordelia, Namuwenge, Norah, Atugonza, Rita, Musoke, Andrew, Musinguzi, Joshua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7252626/
https://www.ncbi.nlm.nih.gov/pubmed/32459822
http://dx.doi.org/10.1371/journal.pone.0232419

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7252626/
https://www.ncbi.nlm.nih.gov/pubmed/32459822
http://dx.doi.org/10.1371/journal.pone.0232419

Ejemplares similares